Uplizna®

Understanding Uplizna® 

Uplizna® (inebilizumab-cdon) is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. By targeting and depleting B cellsthat contribute to the autoimmune attack, Uplizna® helps reduce disease activity, decrease relapse rates, and prevent further damage to the optic nerves and spinal cord.

How Uplizna® Works:

• Targets and depletes B cells that play a role in NMOSD.
• Reduces relapse rates, helping prevent flare-ups of the disease.
• Helps protect the optic nerves and spinal cord, preventing further disability.

FDA Approval:

• Uplizna® (inebilizumab-cdon): Approved for the treatment of NMOSD in adult patients who are anti-AQP4 antibody positive.

For more information, please visit the Uplizna® patient website and speak with your healthcare provider to determine if Uplizna® is the right treatment option for you.